Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

Post Partum Depression Clinical Trial

Official title:

Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04011592
• Other study ID #: HSC-MS-18-0416
• Status: Terminated
• Phase: Phase 2
• Start date: March 4, 2019
• Est. completion date: September 9, 2019

Study information

• Verified date: September 2021
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Postpartum depression is a non-psychotic major or minor depressive episode that occurs during pregnancy or within 12 months of post-partum period. The nature of symptoms is same as depressive episode characterized by depressed mood, anxiety, sleep difficulties, suicidal thoughts, tiredness and diminished interest in pleasurable activities. Severe maternal depression affects children by increasing the risk of emotional and behavioral and physical health problems and cognitive difficulties. Thus early screening and intervention is critical in reducing the negative impact of PND in the mother and child, family and the community. The purpose of this study is to assess the safety, pharmacokinetics and antidepressant efficacy of sub-anesthetic dose of intravenous ketamine in perinatal depression.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: September 9, 2019
• Est. primary completion date: September 9, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Female subjects, ages 18-45 years
• Experienced a major depressive episode in the postpartum period beginning within the first 4 weeks following delivery and with moderate or severe symptoms (>12 EPDS or >14 HAM-D).
• No or partial response to adequate doses of SSRI medications to treat PND for longer than 6 weeks.
• PND patients will be requested to maintain the stable dose of antidepressants while enrolled in the study trial.
• Patients that can speak and read the English language, are able to understand the study procedures and sign the informed consent

Exclusion Criteria:

• No current or past psychosis or severe personality disorder.
• No current substance abuse or dependence.
• No serious and imminent suicidal or homicidal risk.
• No recent or history of major and unstable medical problems that affect brain anatomy, neurochemistry, or function.
• Not diagnosed with cardiovascular disorders.
• No increased risk of laryngospasm or active upper respiratory infections.
• Not diagnosed with an intellectual disability or neurodegenerative diseases.
• Mothers that are currently breastfeeding.
• No current pregnancy.

Related Conditions & MeSH terms

• Depression
• Depression, Postpartum
• Depressive Disorder
• Post Partum Depression

Intervention

Drug:
• Ketamine 0.5 mg/kg
single intravenous infusion of Ketamine (0.5 mg/kg)
• Ketamine 0.2 mg/kg
single intravenous infusion of Ketamine (0.2 mg/kg)

Locations

Country	Name	City	State
United States	The University of Texas Health Science Center at Houston	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Depressed Mood as Indicated by Hamilton Depression Rating Scale (HAM-D) Score	The Hamilton Depression Rating Scale (HAM-D) score ranges from 0-53. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates at least moderate severity of depressive symptoms. The value reported is the score at baseline minus the score 24 hours post-injection.	baseline, 24 hours post-injection
Secondary	Number of Treatment-Emergent Adverse Events		24 hours post-injection
Secondary	Change in Postnatal Depression as Indicated by Edinburgh Postnatal Depression Scale (EPDS) Scale	The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30. Higher scores indicate worse outcome, with a score of 10 or greater indicating depression. The value reported is the score at baseline minus the score at 24 hours post-injection.	baseline, 24 hours post-injection
Secondary	Change in Anxiety as Indicated by Generalized Anxiety Disorder 7-Item (GAD-7) Scale	The Generalized Anxiety Disorder 7-Item (GAD-7) Scale score ranges from 0 to 21, with higher scores indicating greater anxiety. The value reported is the score at baseline minus the score 24 hours post-injection.	baseline, 24 hours post-injection
Secondary	Change in Depression as Indicated by Patient Health Questionnaire (PHQ-9)	The Patient Health Questionnaire (PHQ-9) score ranges from 0 to 27, with greater scores indicating more severe depression.	baseline, 24 hours post-injection
Secondary	Change in Behavioral Suicidal Events (Suicidal Ideation), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)	The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. The first part (Items 1-5) rates an individual's degree of suicidal ideation on a 0-5 scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent and behaviors". The C-SSRS outcomes are categories and have binary responses (yes/no). Suicidal ideation is considered when the patient responds a "yes" answer at any time during treatment to any one of the five suicidal ideation questions (Categories 1-5) on the C-SSRS. The sum of the 5 intensity item scores create a total score (range 0 to 25) to represent the intensity rating (higher scores indicate more severe suicidal ideation).	baseline, 24 hours post-injection
Secondary	Change in Behavioral Suicidal Events (Suicidal Behavior), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)	The questions 6-10 of the C-SSRS are related to suicidal behavior, and the outcome is a simple yes/no response. Suicidal behavior occurs if the patient answers a "yes" at any time during treatment to any one of the five suicidal behavior questions (Categories 6-10) on the C-SSRS.	baseline, 24 hours post-injection